Fundraising FoxEpifrontier Therapeutics
1 known investors
Find your way into Epifrontier Therapeutics
Sign up to see every warm intro you have to Epifrontier Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Epifrontier Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
EpiFrontier Therapeutics is a biotech developing oral epigenetic drugs for beta-globin disorders, with lead candidate EPF-001, a G9a inhibitor raising fetal hemoglobin to treat sickle cell disease and beta-thalassemia.
Investors · 1
UTEClisted by UTECTokyo
How we know: UTEC's portfolio page · Not right? Tell us
Frequently asked questions
- What does Epifrontier Therapeutics do?
- EpiFrontier Therapeutics is a biotech developing oral epigenetic drugs for beta-globin disorders, with lead candidate EPF-001, a G9a inhibitor raising fetal hemoglobin to treat sickle cell disease and beta-thalassemia.
- Who are Epifrontier Therapeutics's investors?
- Epifrontier Therapeutics's investors include UTEC.